Companies › Beijing Konruns Pharmaceutical
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KC1036 unclear - not stated | – | Phase 3 | Esophageal Squamous Cell Carcinoma; Ewing Sarcoma; Esophageal Squamous Cell Carcinoma (ESCC) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06194734 | KC1036 | Phase 3 | Esophageal Squamous Cell Carcinoma | Oncology | Dec 2026 |
| NCT06564272 | KC1036 | Phase 2 | Ewing Sarcoma | Oncology | Apr 2027 |
| NCT07481058 | KC1036 | Phase 2 | Esophageal Squamous Cell Carcinoma (ESCC) | Oncology | Dec 2027 |
No annotated target.
–
LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company Quercis Pharma ABX advanced biochemical compounds
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.